We believe iCAD, Inc. (ICAD), a provider of innovative cancer detection and targeted therapy solutions, has the potential to double over the next twelve months and triple by the end of 2015. Multiple near-term catalysts will accelerate iCAD's top-line growth and position the company to return to GAAP profitability in the next 2-3 quarters, potentially as early as Q4. Given that iCAD's stock is cheap by various valuation metrics, undiscovered, and under-owned, we feel strongly that shares have minimal downside and substantial upside into both year-end and also throughout both 2014 and 2015.
Editor's notes: iCAD has several sources of new revenue growth that haven't been factored into the stock. As it hits profitability and gains leverage, the company's shares could have big upside.